FDA Clearance of Faster Interpretation Time of Chromogenic MRSASelect™
Bio-Rad now have FDA clearance for a faster interpretation time of its existing MRSASelect™ test, a chromogenic medium that is used for the rapid screening of MRSA (methicillin-resistant Staphylococcus aureus).
With high sensitivity and specificity as well as rapid and direct identification, the MRSASelect test can now identify MRSA carriers in as little as 18 hours. Bio-Rad received FDA clearance in the U.S. to market its MRSASelect test with the new interpretation time in June. The test was originally introduced in the U.S. in October 2007.
| |
